NEW HAVEN, Conn., Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant ( ARV-471 ) have been accepted for ...

ARVN

<p>康涅狄格州紐黑文，2025 年 11 月 24 日（GLOBE NEWSWIRE）-- Arvinas, Inc.（納斯達克：ARVN），一家臨牀階段的生物技術公司，正在開發基於靶向蛋白降解的新型藥物，今天宣佈關於 vepdegestrant（ARV-471）的多個摘要已被接受用於</p>

Arvinas Announces Data Presentations from the Vepdegestrant  ( ARV-471 )  Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium  ( SABCS ) 

Arvinas 宣佈將在 2025 年聖安東尼奧乳腺癌研討會上展示 Vepdegestrant（ARV-471）臨牀開發計劃的數據